About E3 ubiquitin-protein ligase RAD18
E3 ubiquitin-protein ligase RAD18 (RAD18) is a protein
from Homo sapiens identified by UniProt accession
Q9NS91, 495 residues long.
MolForge cross-references it against 0 known binders and
150 disease associations.
Target properties
| Protein name | E3 ubiquitin-protein ligase RAD18 |
| UniProt accession | Q9NS91 |
| Gene | RAD18 |
| Organism | Homo sapiens |
| Length | 495 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (150)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.43
- body height · score 0.30
- vital capacity · score 0.27
- age at menopause · score 0.27
- lysosomal storage disease · score 0.26
- uterine fibroid · score 0.21
- breast adenocarcinoma · score 0.18
- neoplasm · score 0.10
- metabolite measurement · score 0.10
- cancer · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9NS91-F1 | alphafold | PREDICTED | 67.00 | — |
Amino-acid sequence (495 residues)
MDSLAESRWP PGLAVMKTID DLLRCGICFE YFNIAMIIPQ CSHNYCSLCI RKFLSYKTQC PTCCVTVTEP DLKNNRILDE LVKSLNFARN HLLQFALESP AKSPASSSSK NLAVKVYTPV ASRQSLKQGS RLMDNFLIRE MSGSTSELLI KENKSKFSPQ KEASPAAKTK ETRSVEEIAP DPSEAKRPEP PSTSTLKQVT KVDCPVCGVN IPESHINKHL DSCLSREEKK ESLRSSVHKR KPLPKTVYNL LSDRDLKKKL KEHGLSIQGN KQQLIKRHQE FVHMYNAQCD ALHPKSAAEI VREIENIEKT RMRLEASKLN ESVMVFTKDQ TEKEIDEIHS KYRKKHKSEF QLLVDQARKG YKKIAGMSQK TVTITKEDES TEKLSSVCMG QEDNMTSVTN HFSQSKLDSP EELEPDREED SSSCIDIQEV LSSSESDSCN SSSSDIIRDL LEEEEAWEAS HKNDLQDTEI SPRQNRRTRA AESAEIEPRN KRNRN
Explore E3 ubiquitin-protein ligase RAD18 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets